PMV Phar­ma gets a whop­ping $74M round to test a new p53 drug in hu­mans

Mu­tant p53 pro­teins have been one of the biggest — and most frus­trat­ing — tar­gets in biotech. But an up­start in Cran­bury, NJ has land­ed a whop­ping $74 mil­lion B round to put its ap­proach to the test.

PMV Phar­ma is fol­low­ing a the­o­ry that’s been fo­cused on be­fore. If mu­tant p53 is the cul­prit, then restor­ing the pro­tein and elim­i­nat­ing the mu­tant es­cape mech­a­nisms that have kept this tar­get out of reach could prove the key to com­ing up with an ef­fec­tive ther­a­py. If they’re right, they can go af­ter a path­way in­volved in rough­ly half of all tu­mors.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.